



Building Better Biologics™

Zymeworks Receives Emerging Life Sciences Company of the Year Award

March 05, 2013

Vancouver, Canada – Zymeworks Inc., a privately held biotherapeutics company focused on the development of best-in-class antibody and next generation protein-based therapeutics, announced today that it had been selected as the recipient of LifeSciences British Columbia's 2013 Emerging Life Sciences Company of the Year Award. The award will be presented on April 4, 2013 during The Faces of Innovation: 15th Annual LifeSciences British Columbia Awards Gala.

"We are honored to be recognized by our peers in the life sciences community for such a prestigious award," says Dr. Ali Tehrani, Zymeworks' President & CEO. "In 2012, Zymeworks' scientific achievements in the field of antibody therapeutics drew international attention, and on the back of further commercial success demonstrated through our commercial partnership with Merck, we've entered 2013 on a high-note. We are excited about the direction and momentum of our preclinical pipeline and partnering activities as we move forward on strategic collaborations surrounding the core platform technologies."

"We would also like to take this opportunity to congratulate one of Zymeworks' independent directors, Ken Galbraith, in being recognized with LSBC's Milton Wong Award for Leadership," adds Dr. Tehrani. "We have had the chance to work closely with Ken in his capacity as a board member over the last few years and have benefited immensely from his guidance. We are privileged to have Ken as a member of the Zymeworks team."

About Zymeworks Inc.

Zymeworks is a privately held biotechnology company developing best-in-class antibody therapeutics for the treatment of oncology, autoimmunity and inflammatory diseases. The company's proprietary ZymeCAD™ structure-guided protein engineering technology and its novel Azymetric™ and AlbuCORE™ platforms enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. Zymeworks is focused on growing its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations.

Contact

Zymeworks Inc.
Dr. Ali Tehrani, Ph.D.
President & CEO
info@zymeworks.com

Source

Zymeworks Inc.